COVID-19 Economic Fallout May Delay Cell And Gene Therapy Reimbursement Solutions
The economic stress on payers caused by the pandemic will cause a setback in the development of payment approaches for regenerative therapy, Blue Cross Blue Shield executive warns.
You may also be interested in...
Drug Coverage In The Pandemic: US Payers Shift Focus From Costs To Access, For Now
Payer concessions to ensure access to drugs during the COVID-19 outbreak offer a benefit to patients and biopharma. But the costs involved could intensify future efforts to manage drug spending.
Gene Therapy Approvals By US FDA Could Double In 2020
CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.
Curative Gene Therapy Coverage May Need Government-Funded Risk Pools
Former US FDA commissioner Scott Gottlieb makes a case for regional or national risk pools to ensure pediatric patients get timely access to gene therapy like the upcoming treatments for sickle cell disease.